GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively.
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
#vaccine
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
#vaccine
2 months ago
